カテゴリー： 世界, 医療/バイオ, LP Information

世界の腹圧性尿失禁用治療薬市場予測 2023年-2029年

【英語タイトル】Global Medicine for Stress Incontinence Market Growth 2023-2029

LP Informationが出版した調査資料（LP23DC01958）・商品コード：LP23DC01958
・発行会社（調査会社）：LP Information
・発行日：2023年11月
・ページ数：113
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後2-3営業日）
・調査対象地域：グローバル、日本、アメリカ、ヨーロッパ、アジア、中国など
・産業分野：医薬品＆医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,660 ⇒換算￥556,320見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD5,490 ⇒換算￥834,480見積依頼/購入/質問フォーム
Corporate User（閲覧人数制限なし）USD7,320 ⇒換算￥1,112,640見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

LPインフォメーションの最新刊調査レポート「世界の腹圧性尿失禁用治療薬市場」は、過去の販売実績から2022年の世界の腹圧性尿失禁用治療薬の総販売量を検討し、2023年から2029年の予測される腹圧性尿失禁用治療薬の販売量を地域別・市場分野別に包括的に分析しています。本調査レポートでは、地域別、市場分野別、サブセクター別の腹圧性尿失禁用治療薬の市場規模を掲載し、XXX百万米ドル規模の世界の腹圧性尿失禁用治療薬市場の詳細な分析を提供します。本インサイトレポートは、世界の腹圧性尿失禁用治療薬業界を包括的に分析し、製品セグメント、企業情報、売上、市場シェア、最新動向、M&A活動に関する主要トレンドを明らかにしています。
また、本レポートでは、加速する世界の腹圧性尿失禁用治療薬市場における各社の独自のポジションをより深く理解するために、腹圧性尿失禁用治療薬製品ポートフォリオ、能力、市場参入戦略、市場でのポジション、海外展開に焦点を当て、主要なグローバル企業の戦略を分析しています。

世界の腹圧性尿失禁用治療薬市場規模は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに成長すると予測され、2023年から2029年までの年平均成長率は000%と予測されます。腹圧性尿失禁用治療薬の米国市場は、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加し、2023年から2029年までのCAGRは000％と予測されています。腹圧性尿失禁用治療薬の中国市場は、2023年から2029年までの年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されます。腹圧性尿失禁用治療薬のヨーロッパ市場は、2023年から2029年にかけて年平均000％成長率で、2022年のXXX百万米ドルから2029年にはXXX百万米ドルに増加すると推定されています。

腹圧性尿失禁用治療薬の世界主要メーカーとしては、Pfizer、 Johnson & Johnson、 Astellas Pharma、 Novartis、 Teva Pharmaceutical Industries、 Mylan、 Sanofi、 GlaxoSmithKline、 Merck、 Eli Lilly and Company、 AstraZeneca、 Bayer、 Ferring Pharmaceuticals、 Endo International、 Allerganなどを掲載しており、売上の面では、世界の2大企業が2022年にほぼ000％のシェアを占めています。

本レポートでは、製品タイプ、用途、主要メーカー、主要地域、国別の腹圧性尿失禁用治療薬市場の包括的な概要、市場シェア、成長機会などの情報を提供しています。

【市場細分化】

この調査では腹圧性尿失禁用治療薬市場をセグメンテーションし、種類別 (α-アドレナリン作動薬、抗コリン薬、デュロキセチン)、用途別 (病院、クリニック、その他)、および地域別 (アジア太平洋、南北アメリカ、ヨーロッパ、および中東・アフリカ) の市場規模を予測しています。

・種類別区分：α-アドレナリン作動薬、抗コリン薬、デュロキセチン

・用途別区分：病院、クリニック、その他

・地域別区分
南北アメリカ（アメリカ、カナダ、メキシコ、ブラジル）
アジア太平洋（中国、日本、韓国、東南アジア、インド、オーストラリア）
ヨーロッパ（ドイツ、フランス、イギリス、イタリア、ロシア）
中東・アフリカ（エジプト、南アフリカ、イスラエル、トルコ、GCC諸国）

【本レポートで扱う主な質問】

・世界の腹圧性尿失禁用治療薬市場の10年間の市場状況・展望は？
・世界および地域別に見た腹圧性尿失禁用治療薬市場成長の要因は何か？
・腹圧性尿失禁用治療薬の市場機会はエンドマーケットの規模によってどのように変化するのか？
・腹圧性尿失禁用治療薬のタイプ別、用途別の内訳は？
・新型コロナウイルス感染症とロシア・ウクライナ戦争の影響は？

********* 目次 *********

レポートの範囲
・市場の紹介
・分析対象期間
・調査の目的
・調査手法
・調査プロセスおよびデータソース
・経済指標
・通貨

エグゼクティブサマリー
・世界市場の概要：腹圧性尿失禁用治療薬の年間販売量2018-2029、地域別現状・将来分析
・腹圧性尿失禁用治療薬の種類別セグメント：α-アドレナリン作動薬、抗コリン薬、デュロキセチン
・腹圧性尿失禁用治療薬の種類別販売量：2018-2023年の販売量、売上、市場シェア、販売価格
・腹圧性尿失禁用治療薬の用途別セグメント：病院、クリニック、その他
・腹圧性尿失禁用治療薬の用途別販売量：2018-2023年の販売量、売上、市場シェア、販売価格

企業別世界の腹圧性尿失禁用治療薬市場
・企業別のグローバル腹圧性尿失禁用治療薬市場データ：2018-2023年の年間販売量、市場シェア
・企業別の腹圧性尿失禁用治療薬の年間売上：2018-2023年の売上、市場シェア
・企業別の腹圧性尿失禁用治療薬販売価格
・主要企業の腹圧性尿失禁用治療薬生産地域、販売地域、製品タイプ
・市場集中度分析
・新製品および潜在的な参加者
・合併と買収、拡大

腹圧性尿失禁用治療薬の地域別レビュー
・地域別の腹圧性尿失禁用治療薬市場規模2018-2023：年間販売量、売上
・主要国別の腹圧性尿失禁用治療薬市場規模2018-2023：年間販売量、売上
・南北アメリカの腹圧性尿失禁用治療薬販売の成長
・アジア太平洋の腹圧性尿失禁用治療薬販売の成長
・ヨーロッパの腹圧性尿失禁用治療薬販売の成長
・中東・アフリカの腹圧性尿失禁用治療薬販売の成長

南北アメリカ市場
・南北アメリカの国別の腹圧性尿失禁用治療薬販売量、売上（2018-2023）
・南北アメリカの腹圧性尿失禁用治療薬の種類別販売量
・南北アメリカの腹圧性尿失禁用治療薬の用途別販売量
・アメリカ市場
・カナダ市場
・メキシコ市場
・ブラジル市場

アジア太平洋市場
・アジア太平洋の国別の腹圧性尿失禁用治療薬販売量、売上（2018-2023）
・アジア太平洋の腹圧性尿失禁用治療薬の種類別販売量
・アジア太平洋の腹圧性尿失禁用治療薬の用途別販売量
・中国市場
・日本市場
・韓国市場
・東南アジア市場
・インド市場
・オーストラリア市場
・台湾市場

ヨーロッパ市場
・ヨーロッパの国別の腹圧性尿失禁用治療薬販売量、売上（2018-2023）
・ヨーロッパの腹圧性尿失禁用治療薬の種類別販売量
・ヨーロッパの腹圧性尿失禁用治療薬の用途別販売量
・ドイツ市場
・フランス市場
・イギリス市場
・イタリア市場
・ロシア市場

中東・アフリカ市場
・中東・アフリカの国別の腹圧性尿失禁用治療薬販売量、売上（2018-2023）
・中東・アフリカの腹圧性尿失禁用治療薬の種類別販売量
・中東・アフリカの腹圧性尿失禁用治療薬の用途別販売量
・エジプト市場
・南アフリカ市場
・イスラエル市場
・トルコ市場
・GCC諸国市場

市場の成長要因、課題、動向
・市場の成長要因および成長機会分析
・市場の課題およびリスク
・市場動向

製造コスト構造分析
・原材料とサプライヤー
・腹圧性尿失禁用治療薬の製造コスト構造分析
・腹圧性尿失禁用治療薬の製造プロセス分析
・腹圧性尿失禁用治療薬の産業チェーン構造

マーケティング、販売業者および顧客
・販売チャンネル：直接販売チャンネル、間接販売チャンネル
・腹圧性尿失禁用治療薬の主要なグローバル販売業者
・腹圧性尿失禁用治療薬の主要なグローバル顧客

地域別の腹圧性尿失禁用治療薬市場予測レビュー
・地域別の腹圧性尿失禁用治療薬市場規模予測（2024-2029）
・南北アメリカの国別予測
・アジア太平洋の国別予測
・ヨーロッパの国別予測
・腹圧性尿失禁用治療薬の種類別市場規模予測
・腹圧性尿失禁用治療薬の用途別市場規模予測

主要企業分析
Pfizer、 Johnson & Johnson、 Astellas Pharma、 Novartis、 Teva Pharmaceutical Industries、 Mylan、 Sanofi、 GlaxoSmithKline、 Merck、 Eli Lilly and Company、 AstraZeneca、 Bayer、 Ferring Pharmaceuticals、 Endo International、 Allergan
・企業情報
・腹圧性尿失禁用治療薬製品
・腹圧性尿失禁用治療薬販売量、売上、価格、粗利益（2018-2023）
・主要ビジネス概要
・最新動向

調査結果および結論

The global Medicine for Stress Incontinence market size is projected to grow from US$ 33 million in 2022 to US$ 48 million in 2029; it is expected to grow at a CAGR of 5.5% from 2023 to 2029.
United States market for Medicine for Stress Incontinence is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Medicine for Stress Incontinence is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Medicine for Stress Incontinence is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Medicine for Stress Incontinence players cover Pfizer, Johnson & Johnson, Astellas Pharma, Novartis, Teva Pharmaceutical Industries, Mylan, Sanofi, GlaxoSmithKline and Merck, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Stress urinary incontinence is a type of urinary incontinence that occurs when there is increased pressure on the bladder, such as when coughing, sneezing, or exercising. Medications are not usually the first line of treatment for stress urinary incontinence, but they may be prescribed in some cases.
LPI (LP Information)’ newest research report, the “Medicine for Stress Incontinence Industry Forecast” looks at past sales and reviews total world Medicine for Stress Incontinence sales in 2022, providing a comprehensive analysis by region and market sector of projected Medicine for Stress Incontinence sales for 2023 through 2029. With Medicine for Stress Incontinence sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Medicine for Stress Incontinence industry.
This Insight Report provides a comprehensive analysis of the global Medicine for Stress Incontinence landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Medicine for Stress Incontinence portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Medicine for Stress Incontinence market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Medicine for Stress Incontinence and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Medicine for Stress Incontinence.
This report presents a comprehensive overview, market shares, and growth opportunities of Medicine for Stress Incontinence market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Alpha-adrenergic Agonists
Anticholinergics
Duloxetine
Segmentation by application
Hospital
Clinic
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company’s coverage, product portfolio, its market penetration.
Pfizer
Johnson & Johnson
Astellas Pharma
Novartis
Teva Pharmaceutical Industries
Mylan
Sanofi
GlaxoSmithKline
Merck
Eli Lilly and Company
AstraZeneca
Bayer
Ferring Pharmaceuticals
Endo International
Allergan
Key Questions Addressed in this Report
What is the 10-year outlook for the global Medicine for Stress Incontinence market?
What factors are driving Medicine for Stress Incontinence market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Medicine for Stress Incontinence market opportunities vary by end market size?
How does Medicine for Stress Incontinence break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?

❖ レポートの目次 ❖

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Medicine for Stress Incontinence Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Medicine for Stress Incontinence by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Medicine for Stress Incontinence by Country/Region, 2018, 2022 & 2029
2.2 Medicine for Stress Incontinence Segment by Type
2.2.1 Alpha-adrenergic Agonists
2.2.2 Anticholinergics
2.2.3 Duloxetine
2.3 Medicine for Stress Incontinence Sales by Type
2.3.1 Global Medicine for Stress Incontinence Sales Market Share by Type (2018-2023)
2.3.2 Global Medicine for Stress Incontinence Revenue and Market Share by Type (2018-2023)
2.3.3 Global Medicine for Stress Incontinence Sale Price by Type (2018-2023)
2.4 Medicine for Stress Incontinence Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Others
2.5 Medicine for Stress Incontinence Sales by Application
2.5.1 Global Medicine for Stress Incontinence Sale Market Share by Application (2018-2023)
2.5.2 Global Medicine for Stress Incontinence Revenue and Market Share by Application (2018-2023)
2.5.3 Global Medicine for Stress Incontinence Sale Price by Application (2018-2023)
3 Global Medicine for Stress Incontinence by Company
3.1 Global Medicine for Stress Incontinence Breakdown Data by Company
3.1.1 Global Medicine for Stress Incontinence Annual Sales by Company (2018-2023)
3.1.2 Global Medicine for Stress Incontinence Sales Market Share by Company (2018-2023)
3.2 Global Medicine for Stress Incontinence Annual Revenue by Company (2018-2023)
3.2.1 Global Medicine for Stress Incontinence Revenue by Company (2018-2023)
3.2.2 Global Medicine for Stress Incontinence Revenue Market Share by Company (2018-2023)
3.3 Global Medicine for Stress Incontinence Sale Price by Company
3.4 Key Manufacturers Medicine for Stress Incontinence Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Medicine for Stress Incontinence Product Location Distribution
3.4.2 Players Medicine for Stress Incontinence Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Medicine for Stress Incontinence by Geographic Region
4.1 World Historic Medicine for Stress Incontinence Market Size by Geographic Region (2018-2023)
4.1.1 Global Medicine for Stress Incontinence Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Medicine for Stress Incontinence Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Medicine for Stress Incontinence Market Size by Country/Region (2018-2023)
4.2.1 Global Medicine for Stress Incontinence Annual Sales by Country/Region (2018-2023)
4.2.2 Global Medicine for Stress Incontinence Annual Revenue by Country/Region (2018-2023)
4.3 Americas Medicine for Stress Incontinence Sales Growth
4.4 APAC Medicine for Stress Incontinence Sales Growth
4.5 Europe Medicine for Stress Incontinence Sales Growth
4.6 Middle East & Africa Medicine for Stress Incontinence Sales Growth
5 Americas
5.1 Americas Medicine for Stress Incontinence Sales by Country
5.1.1 Americas Medicine for Stress Incontinence Sales by Country (2018-2023)
5.1.2 Americas Medicine for Stress Incontinence Revenue by Country (2018-2023)
5.2 Americas Medicine for Stress Incontinence Sales by Type
5.3 Americas Medicine for Stress Incontinence Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Medicine for Stress Incontinence Sales by Region
6.1.1 APAC Medicine for Stress Incontinence Sales by Region (2018-2023)
6.1.2 APAC Medicine for Stress Incontinence Revenue by Region (2018-2023)
6.2 APAC Medicine for Stress Incontinence Sales by Type
6.3 APAC Medicine for Stress Incontinence Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Medicine for Stress Incontinence by Country
7.1.1 Europe Medicine for Stress Incontinence Sales by Country (2018-2023)
7.1.2 Europe Medicine for Stress Incontinence Revenue by Country (2018-2023)
7.2 Europe Medicine for Stress Incontinence Sales by Type
7.3 Europe Medicine for Stress Incontinence Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Medicine for Stress Incontinence by Country
8.1.1 Middle East & Africa Medicine for Stress Incontinence Sales by Country (2018-2023)
8.1.2 Middle East & Africa Medicine for Stress Incontinence Revenue by Country (2018-2023)
8.2 Middle East & Africa Medicine for Stress Incontinence Sales by Type
8.3 Middle East & Africa Medicine for Stress Incontinence Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Medicine for Stress Incontinence
10.3 Manufacturing Process Analysis of Medicine for Stress Incontinence
10.4 Industry Chain Structure of Medicine for Stress Incontinence
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Medicine for Stress Incontinence Distributors
11.3 Medicine for Stress Incontinence Customer
12 World Forecast Review for Medicine for Stress Incontinence by Geographic Region
12.1 Global Medicine for Stress Incontinence Market Size Forecast by Region
12.1.1 Global Medicine for Stress Incontinence Forecast by Region (2024-2029)
12.1.2 Global Medicine for Stress Incontinence Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Medicine for Stress Incontinence Forecast by Type
12.7 Global Medicine for Stress Incontinence Forecast by Application
13 Key Players Analysis
13.1 Pfizer
13.1.1 Pfizer Company Information
13.1.2 Pfizer Medicine for Stress Incontinence Product Portfolios and Specifications
13.1.3 Pfizer Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Pfizer Main Business Overview
13.1.5 Pfizer Latest Developments
13.2 Johnson & Johnson
13.2.1 Johnson & Johnson Company Information
13.2.2 Johnson & Johnson Medicine for Stress Incontinence Product Portfolios and Specifications
13.2.3 Johnson & Johnson Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Johnson & Johnson Main Business Overview
13.2.5 Johnson & Johnson Latest Developments
13.3 Astellas Pharma
13.3.1 Astellas Pharma Company Information
13.3.2 Astellas Pharma Medicine for Stress Incontinence Product Portfolios and Specifications
13.3.3 Astellas Pharma Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Astellas Pharma Main Business Overview
13.3.5 Astellas Pharma Latest Developments
13.4 Novartis
13.4.1 Novartis Company Information
13.4.2 Novartis Medicine for Stress Incontinence Product Portfolios and Specifications
13.4.3 Novartis Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Novartis Main Business Overview
13.4.5 Novartis Latest Developments
13.5 Teva Pharmaceutical Industries
13.5.1 Teva Pharmaceutical Industries Company Information
13.5.2 Teva Pharmaceutical Industries Medicine for Stress Incontinence Product Portfolios and Specifications
13.5.3 Teva Pharmaceutical Industries Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Teva Pharmaceutical Industries Main Business Overview
13.5.5 Teva Pharmaceutical Industries Latest Developments
13.6 Mylan
13.6.1 Mylan Company Information
13.6.2 Mylan Medicine for Stress Incontinence Product Portfolios and Specifications
13.6.3 Mylan Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Mylan Main Business Overview
13.6.5 Mylan Latest Developments
13.7 Sanofi
13.7.1 Sanofi Company Information
13.7.2 Sanofi Medicine for Stress Incontinence Product Portfolios and Specifications
13.7.3 Sanofi Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 Sanofi Main Business Overview
13.7.5 Sanofi Latest Developments
13.8 GlaxoSmithKline
13.8.1 GlaxoSmithKline Company Information
13.8.2 GlaxoSmithKline Medicine for Stress Incontinence Product Portfolios and Specifications
13.8.3 GlaxoSmithKline Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 GlaxoSmithKline Main Business Overview
13.8.5 GlaxoSmithKline Latest Developments
13.9 Merck
13.9.1 Merck Company Information
13.9.2 Merck Medicine for Stress Incontinence Product Portfolios and Specifications
13.9.3 Merck Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 Merck Main Business Overview
13.9.5 Merck Latest Developments
13.10 Eli Lilly and Company
13.10.1 Eli Lilly and Company Company Information
13.10.2 Eli Lilly and Company Medicine for Stress Incontinence Product Portfolios and Specifications
13.10.3 Eli Lilly and Company Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Eli Lilly and Company Main Business Overview
13.10.5 Eli Lilly and Company Latest Developments
13.11 AstraZeneca
13.11.1 AstraZeneca Company Information
13.11.2 AstraZeneca Medicine for Stress Incontinence Product Portfolios and Specifications
13.11.3 AstraZeneca Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 AstraZeneca Main Business Overview
13.11.5 AstraZeneca Latest Developments
13.12 Bayer
13.12.1 Bayer Company Information
13.12.2 Bayer Medicine for Stress Incontinence Product Portfolios and Specifications
13.12.3 Bayer Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Bayer Main Business Overview
13.12.5 Bayer Latest Developments
13.13 Ferring Pharmaceuticals
13.13.1 Ferring Pharmaceuticals Company Information
13.13.2 Ferring Pharmaceuticals Medicine for Stress Incontinence Product Portfolios and Specifications
13.13.3 Ferring Pharmaceuticals Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 Ferring Pharmaceuticals Main Business Overview
13.13.5 Ferring Pharmaceuticals Latest Developments
13.14 Endo International
13.14.1 Endo International Company Information
13.14.2 Endo International Medicine for Stress Incontinence Product Portfolios and Specifications
13.14.3 Endo International Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Endo International Main Business Overview
13.14.5 Endo International Latest Developments
13.15 Allergan
13.15.1 Allergan Company Information
13.15.2 Allergan Medicine for Stress Incontinence Product Portfolios and Specifications
13.15.3 Allergan Medicine for Stress Incontinence Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Allergan Main Business Overview
13.15.5 Allergan Latest Developments
14 Research Findings and Conclusion

List of Tables
Table 1. Medicine for Stress Incontinence Annual Sales CAGR by Geographic Region (2018, 2022 & 2029) & ($ millions)
Table 2. Medicine for Stress Incontinence Annual Sales CAGR by Country/Region (2018, 2022 & 2029) & ($ millions)
Table 3. Major Players of Alpha-adrenergic Agonists
Table 4. Major Players of Anticholinergics
Table 5. Major Players of Duloxetine
Table 6. Global Medicine for Stress Incontinence Sales by Type (2018-2023) & (K Units)
Table 7. Global Medicine for Stress Incontinence Sales Market Share by Type (2018-2023)
Table 8. Global Medicine for Stress Incontinence Revenue by Type (2018-2023) & ($ million)
Table 9. Global Medicine for Stress Incontinence Revenue Market Share by Type (2018-2023)
Table 10. Global Medicine for Stress Incontinence Sale Price by Type (2018-2023) & (US$/Unit)
Table 11. Global Medicine for Stress Incontinence Sales by Application (2018-2023) & (K Units)
Table 12. Global Medicine for Stress Incontinence Sales Market Share by Application (2018-2023)
Table 13. Global Medicine for Stress Incontinence Revenue by Application (2018-2023)
Table 14. Global Medicine for Stress Incontinence Revenue Market Share by Application (2018-2023)
Table 15. Global Medicine for Stress Incontinence Sale Price by Application (2018-2023) & (US$/Unit)
Table 16. Global Medicine for Stress Incontinence Sales by Company (2018-2023) & (K Units)
Table 17. Global Medicine for Stress Incontinence Sales Market Share by Company (2018-2023)
Table 18. Global Medicine for Stress Incontinence Revenue by Company (2018-2023) ($ Millions)
Table 19. Global Medicine for Stress Incontinence Revenue Market Share by Company (2018-2023)
Table 20. Global Medicine for Stress Incontinence Sale Price by Company (2018-2023) & (US$/Unit)
Table 21. Key Manufacturers Medicine for Stress Incontinence Producing Area Distribution and Sales Area
Table 22. Players Medicine for Stress Incontinence Products Offered
Table 23. Medicine for Stress Incontinence Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
Table 24. New Products and Potential Entrants
Table 25. Mergers & Acquisitions, Expansion
Table 26. Global Medicine for Stress Incontinence Sales by Geographic Region (2018-2023) & (K Units)
Table 27. Global Medicine for Stress Incontinence Sales Market Share Geographic Region (2018-2023)
Table 28. Global Medicine for Stress Incontinence Revenue by Geographic Region (2018-2023) & ($ millions)
Table 29. Global Medicine for Stress Incontinence Revenue Market Share by Geographic Region (2018-2023)
Table 30. Global Medicine for Stress Incontinence Sales by Country/Region (2018-2023) & (K Units)
Table 31. Global Medicine for Stress Incontinence Sales Market Share by Country/Region (2018-2023)
Table 32. Global Medicine for Stress Incontinence Revenue by Country/Region (2018-2023) & ($ millions)
Table 33. Global Medicine for Stress Incontinence Revenue Market Share by Country/Region (2018-2023)
Table 34. Americas Medicine for Stress Incontinence Sales by Country (2018-2023) & (K Units)
Table 35. Americas Medicine for Stress Incontinence Sales Market Share by Country (2018-2023)
Table 36. Americas Medicine for Stress Incontinence Revenue by Country (2018-2023) & ($ Millions)
Table 37. Americas Medicine for Stress Incontinence Revenue Market Share by Country (2018-2023)
Table 38. Americas Medicine for Stress Incontinence Sales by Type (2018-2023) & (K Units)
Table 39. Americas Medicine for Stress Incontinence Sales by Application (2018-2023) & (K Units)
Table 40. APAC Medicine for Stress Incontinence Sales by Region (2018-2023) & (K Units)
Table 41. APAC Medicine for Stress Incontinence Sales Market Share by Region (2018-2023)
Table 42. APAC Medicine for Stress Incontinence Revenue by Region (2018-2023) & ($ Millions)
Table 43. APAC Medicine for Stress Incontinence Revenue Market Share by Region (2018-2023)
Table 44. APAC Medicine for Stress Incontinence Sales by Type (2018-2023) & (K Units)
Table 45. APAC Medicine for Stress Incontinence Sales by Application (2018-2023) & (K Units)
Table 46. Europe Medicine for Stress Incontinence Sales by Country (2018-2023) & (K Units)
Table 47. Europe Medicine for Stress Incontinence Sales Market Share by Country (2018-2023)
Table 48. Europe Medicine for Stress Incontinence Revenue by Country (2018-2023) & ($ Millions)
Table 49. Europe Medicine for Stress Incontinence Revenue Market Share by Country (2018-2023)
Table 50. Europe Medicine for Stress Incontinence Sales by Type (2018-2023) & (K Units)
Table 51. Europe Medicine for Stress Incontinence Sales by Application (2018-2023) & (K Units)
Table 52. Middle East & Africa Medicine for Stress Incontinence Sales by Country (2018-2023) & (K Units)
Table 53. Middle East & Africa Medicine for Stress Incontinence Sales Market Share by Country (2018-2023)
Table 54. Middle East & Africa Medicine for Stress Incontinence Revenue by Country (2018-2023) & ($ Millions)
Table 55. Middle East & Africa Medicine for Stress Incontinence Revenue Market Share by Country (2018-2023)
Table 56. Middle East & Africa Medicine for Stress Incontinence Sales by Type (2018-2023) & (K Units)
Table 57. Middle East & Africa Medicine for Stress Incontinence Sales by Application (2018-2023) & (K Units)
Table 58. Key Market Drivers & Growth Opportunities of Medicine for Stress Incontinence
Table 59. Key Market Challenges & Risks of Medicine for Stress Incontinence
Table 60. Key Industry Trends of Medicine for Stress Incontinence
Table 61. Medicine for Stress Incontinence Raw Material
Table 62. Key Suppliers of Raw Materials
Table 63. Medicine for Stress Incontinence Distributors List
Table 64. Medicine for Stress Incontinence Customer List
Table 65. Global Medicine for Stress Incontinence Sales Forecast by Region (2024-2029) & (K Units)
Table 66. Global Medicine for Stress Incontinence Revenue Forecast by Region (2024-2029) & ($ millions)
Table 67. Americas Medicine for Stress Incontinence Sales Forecast by Country (2024-2029) & (K Units)
Table 68. Americas Medicine for Stress Incontinence Revenue Forecast by Country (2024-2029) & ($ millions)
Table 69. APAC Medicine for Stress Incontinence Sales Forecast by Region (2024-2029) & (K Units)
Table 70. APAC Medicine for Stress Incontinence Revenue Forecast by Region (2024-2029) & ($ millions)
Table 71. Europe Medicine for Stress Incontinence Sales Forecast by Country (2024-2029) & (K Units)
Table 72. Europe Medicine for Stress Incontinence Revenue Forecast by Country (2024-2029) & ($ millions)
Table 73. Middle East & Africa Medicine for Stress Incontinence Sales Forecast by Country (2024-2029) & (K Units)
Table 74. Middle East & Africa Medicine for Stress Incontinence Revenue Forecast by Country (2024-2029) & ($ millions)
Table 75. Global Medicine for Stress Incontinence Sales Forecast by Type (2024-2029) & (K Units)
Table 76. Global Medicine for Stress Incontinence Revenue Forecast by Type (2024-2029) & ($ Millions)
Table 77. Global Medicine for Stress Incontinence Sales Forecast by Application (2024-2029) & (K Units)
Table 78. Global Medicine for Stress Incontinence Revenue Forecast by Application (2024-2029) & ($ Millions)
Table 79. Pfizer Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 80. Pfizer Medicine for Stress Incontinence Product Portfolios and Specifications
Table 81. Pfizer Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 82. Pfizer Main Business
Table 83. Pfizer Latest Developments
Table 84. Johnson & Johnson Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 85. Johnson & Johnson Medicine for Stress Incontinence Product Portfolios and Specifications
Table 86. Johnson & Johnson Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 87. Johnson & Johnson Main Business
Table 88. Johnson & Johnson Latest Developments
Table 89. Astellas Pharma Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 90. Astellas Pharma Medicine for Stress Incontinence Product Portfolios and Specifications
Table 91. Astellas Pharma Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 92. Astellas Pharma Main Business
Table 93. Astellas Pharma Latest Developments
Table 94. Novartis Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 95. Novartis Medicine for Stress Incontinence Product Portfolios and Specifications
Table 96. Novartis Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 97. Novartis Main Business
Table 98. Novartis Latest Developments
Table 99. Teva Pharmaceutical Industries Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 100. Teva Pharmaceutical Industries Medicine for Stress Incontinence Product Portfolios and Specifications
Table 101. Teva Pharmaceutical Industries Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 102. Teva Pharmaceutical Industries Main Business
Table 103. Teva Pharmaceutical Industries Latest Developments
Table 104. Mylan Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 105. Mylan Medicine for Stress Incontinence Product Portfolios and Specifications
Table 106. Mylan Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 107. Mylan Main Business
Table 108. Mylan Latest Developments
Table 109. Sanofi Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 110. Sanofi Medicine for Stress Incontinence Product Portfolios and Specifications
Table 111. Sanofi Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 112. Sanofi Main Business
Table 113. Sanofi Latest Developments
Table 114. GlaxoSmithKline Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 115. GlaxoSmithKline Medicine for Stress Incontinence Product Portfolios and Specifications
Table 116. GlaxoSmithKline Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 117. GlaxoSmithKline Main Business
Table 118. GlaxoSmithKline Latest Developments
Table 119. Merck Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 120. Merck Medicine for Stress Incontinence Product Portfolios and Specifications
Table 121. Merck Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 122. Merck Main Business
Table 123. Merck Latest Developments
Table 124. Eli Lilly and Company Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 125. Eli Lilly and Company Medicine for Stress Incontinence Product Portfolios and Specifications
Table 126. Eli Lilly and Company Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 127. Eli Lilly and Company Main Business
Table 128. Eli Lilly and Company Latest Developments
Table 129. AstraZeneca Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 130. AstraZeneca Medicine for Stress Incontinence Product Portfolios and Specifications
Table 131. AstraZeneca Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 132. AstraZeneca Main Business
Table 133. AstraZeneca Latest Developments
Table 134. Bayer Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 135. Bayer Medicine for Stress Incontinence Product Portfolios and Specifications
Table 136. Bayer Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 137. Bayer Main Business
Table 138. Bayer Latest Developments
Table 139. Ferring Pharmaceuticals Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 140. Ferring Pharmaceuticals Medicine for Stress Incontinence Product Portfolios and Specifications
Table 141. Ferring Pharmaceuticals Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 142. Ferring Pharmaceuticals Main Business
Table 143. Ferring Pharmaceuticals Latest Developments
Table 144. Endo International Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 145. Endo International Medicine for Stress Incontinence Product Portfolios and Specifications
Table 146. Endo International Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 147. Endo International Main Business
Table 148. Endo International Latest Developments
Table 149. Allergan Basic Information, Medicine for Stress Incontinence Manufacturing Base, Sales Area and Its Competitors
Table 150. Allergan Medicine for Stress Incontinence Product Portfolios and Specifications
Table 151. Allergan Medicine for Stress Incontinence Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2018-2023)
Table 152. Allergan Main Business
Table 153. Allergan Latest Developments
List of Figures
Figure 1. Picture of Medicine for Stress Incontinence
Figure 2. Medicine for Stress Incontinence Report Years Considered
Figure 3. Research Objectives
Figure 4. Research Methodology
Figure 5. Research Process and Data Source
Figure 6. Global Medicine for Stress Incontinence Sales Growth Rate 2018-2029 (K Units)
Figure 7. Global Medicine for Stress Incontinence Revenue Growth Rate 2018-2029 ($ Millions)
Figure 8. Medicine for Stress Incontinence Sales by Region (2018, 2022 & 2029) & ($ Millions)
Figure 9. Product Picture of Alpha-adrenergic Agonists
Figure 10. Product Picture of Anticholinergics
Figure 11. Product Picture of Duloxetine
Figure 12. Global Medicine for Stress Incontinence Sales Market Share by Type in 2022
Figure 13. Global Medicine for Stress Incontinence Revenue Market Share by Type (2018-2023)
Figure 14. Medicine for Stress Incontinence Consumed in Hospital
Figure 15. Global Medicine for Stress Incontinence Market: Hospital (2018-2023) & (K Units)
Figure 16. Medicine for Stress Incontinence Consumed in Clinic
Figure 17. Global Medicine for Stress Incontinence Market: Clinic (2018-2023) & (K Units)
Figure 18. Medicine for Stress Incontinence Consumed in Others
Figure 19. Global Medicine for Stress Incontinence Market: Others (2018-2023) & (K Units)
Figure 20. Global Medicine for Stress Incontinence Sales Market Share by Application (2022)
Figure 21. Global Medicine for Stress Incontinence Revenue Market Share by Application in 2022
Figure 22. Medicine for Stress Incontinence Sales Market by Company in 2022 (K Units)
Figure 23. Global Medicine for Stress Incontinence Sales Market Share by Company in 2022
Figure 24. Medicine for Stress Incontinence Revenue Market by Company in 2022 ($ Million)
Figure 25. Global Medicine for Stress Incontinence Revenue Market Share by Company in 2022
Figure 26. Global Medicine for Stress Incontinence Sales Market Share by Geographic Region (2018-2023)
Figure 27. Global Medicine for Stress Incontinence Revenue Market Share by Geographic Region in 2022
Figure 28. Americas Medicine for Stress Incontinence Sales 2018-2023 (K Units)
Figure 29. Americas Medicine for Stress Incontinence Revenue 2018-2023 ($ Millions)
Figure 30. APAC Medicine for Stress Incontinence Sales 2018-2023 (K Units)
Figure 31. APAC Medicine for Stress Incontinence Revenue 2018-2023 ($ Millions)
Figure 32. Europe Medicine for Stress Incontinence Sales 2018-2023 (K Units)
Figure 33. Europe Medicine for Stress Incontinence Revenue 2018-2023 ($ Millions)
Figure 34. Middle East & Africa Medicine for Stress Incontinence Sales 2018-2023 (K Units)
Figure 35. Middle East & Africa Medicine for Stress Incontinence Revenue 2018-2023 ($ Millions)
Figure 36. Americas Medicine for Stress Incontinence Sales Market Share by Country in 2022
Figure 37. Americas Medicine for Stress Incontinence Revenue Market Share by Country in 2022
Figure 38. Americas Medicine for Stress Incontinence Sales Market Share by Type (2018-2023)
Figure 39. Americas Medicine for Stress Incontinence Sales Market Share by Application (2018-2023)
Figure 40. United States Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 41. Canada Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 42. Mexico Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 43. Brazil Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 44. APAC Medicine for Stress Incontinence Sales Market Share by Region in 2022
Figure 45. APAC Medicine for Stress Incontinence Revenue Market Share by Regions in 2022
Figure 46. APAC Medicine for Stress Incontinence Sales Market Share by Type (2018-2023)
Figure 47. APAC Medicine for Stress Incontinence Sales Market Share by Application (2018-2023)
Figure 48. China Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 49. Japan Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 50. South Korea Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 51. Southeast Asia Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 52. India Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 53. Australia Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 54. China Taiwan Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 55. Europe Medicine for Stress Incontinence Sales Market Share by Country in 2022
Figure 56. Europe Medicine for Stress Incontinence Revenue Market Share by Country in 2022
Figure 57. Europe Medicine for Stress Incontinence Sales Market Share by Type (2018-2023)
Figure 58. Europe Medicine for Stress Incontinence Sales Market Share by Application (2018-2023)
Figure 59. Germany Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 60. France Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 61. UK Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 62. Italy Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 63. Russia Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 64. Middle East & Africa Medicine for Stress Incontinence Sales Market Share by Country in 2022
Figure 65. Middle East & Africa Medicine for Stress Incontinence Revenue Market Share by Country in 2022
Figure 66. Middle East & Africa Medicine for Stress Incontinence Sales Market Share by Type (2018-2023)
Figure 67. Middle East & Africa Medicine for Stress Incontinence Sales Market Share by Application (2018-2023)
Figure 68. Egypt Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 69. South Africa Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 70. Israel Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 71. Turkey Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 72. GCC Country Medicine for Stress Incontinence Revenue Growth 2018-2023 ($ Millions)
Figure 73. Manufacturing Cost Structure Analysis of Medicine for Stress Incontinence in 2022
Figure 74. Manufacturing Process Analysis of Medicine for Stress Incontinence
Figure 75. Industry Chain Structure of Medicine for Stress Incontinence
Figure 76. Channels of Distribution
Figure 77. Global Medicine for Stress Incontinence Sales Market Forecast by Region (2024-2029)
Figure 78. Global Medicine for Stress Incontinence Revenue Market Share Forecast by Region (2024-2029)
Figure 79. Global Medicine for Stress Incontinence Sales Market Share Forecast by Type (2024-2029)
Figure 80. Global Medicine for Stress Incontinence Revenue Market Share Forecast by Type (2024-2029)
Figure 81. Global Medicine for Stress Incontinence Sales Market Share Forecast by Application (2024-2029)
Figure 82. Global Medicine for Stress Incontinence Revenue Market Share Forecast by Application (2024-2029)


★調査レポート[世界の腹圧性尿失禁用治療薬市場予測 2023年-2029年] (コード：LP23DC01958)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の腹圧性尿失禁用治療薬市場予測 2023年-2029年]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界の非外科的尿失禁治療市場予測 2023年-2029年
  • 世界の腹圧性尿失禁用ペッサリー市場2022年：失禁リングペッサリー、サポート付きリングペッサリー、失禁ディッシュ、その他
  • 世界の薬用乾燥剤市場予測 2023年-2029年
  • 世界の鼻炎薬市場予測 2023年-2029年
  • 世界の医療用内服薬市場予測 2023年-2029年

    • ◆H&Iグローバルリサーチのお客様（例）◆